Skip to main content

Advertisement

Table 2 Clinical parameters of the model (annual rates of complications)

From: Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist

  Thromboembolism Hemorrhage Death
Base analysis (deterministic)    
Annual rate Hvp 0.052 0.079 0.093
RR PSM vs Hvp 0.59 (0.46–0.77) 1 0.76 (0.58–0.99)
RR Dabi vs Hvp 0.59 (0.46–0.77) 1 0.76 (0.58–0.99)
RR PCpc vs Hvp 1 1 1
Base analysis (probabilistic)    
Annual rate Hvp 0.052 0.079 0.093
RR PSM vs Hvp 0.59 (0.46–0.77) 0.96 (0.81–1.13) 0.76 (0.58–0.99)
RR Dabi vs Hvp 0.66 (0.53–0.82) 0.93 (0.81–1.07) 0.88 (0.77–1.00)
Other variables    
% of non-fatal complications that cause permanent disability 60 % 10 % -
% of patients with permanent disability who continue therapy 50 % 50 % -
Utility without complications 0.659 0.659 -
Utility with complication 0.447 0.215 -
  1. RR Relative risk; PSM Patient self-management; PCpc Primary care with portable coagulometer; Hpc Hospital with portable coagulometer; Hvp Hospital with venipuncture; Dabi: Dabigatran
  2. Sources: adapted from Brown A. et al. (2007) [12], Alonso-Coello, P et al. [21, 37]